Committee Composition

Jeff is NxStage's Founder, President and Chief Executive Officer, and is a member of its Board of Directors. Jeff has over 20 years of in-depth management experience with companies developing, marketing and manufacturing products for End Stage Renal Disease patients. He has led NxStage since its inception, guiding it through all of its developmental phases to the successful initiation of commercial activity, its initial public offering and the recent acquisition of Medisystems. Prior to founding NxStage, he co-founded Vasca, Inc., a company providing innovative implantable access devices, where he was the President and CEO, as well as Chairman of the Board. He gained significant renal industry experience during his nine years at Gambro, Inc., in the Renal Division, with his last position as Director of Marketing and Advanced Technologies. During his career he has been an inventor on 50 U.S. patents for medical devices.

Jeff received his BS in Industrial Engineering from Lehigh University.
Recent Stock Transactions by Jeffrey H. Burbank
Date Type Shares Traded Price Range
Apr 20, 2017 Automatic Sell 3,000 27.28
Apr 19, 2017 Automatic Sell 3,000 26.65
Mar 22, 2017 Automatic Sell 3,000 27.42
Mar 21, 2017 Automatic Sell 3,000 27.72
Mar 3, 2017 Disposition (Non Open Market) 13,185 28.31
Mar 3, 2017 Option Execute 28,022 n/a
Feb 23, 2017 Automatic Sell 7,500 28.97
Feb 22, 2017 Automatic Sell 7,500 29.01
Feb 10, 2017 Disposition (Non Open Market) 49,555 28.38
Feb 10, 2017 Option Execute 133,188 9.96 - 18.59
Jan 18, 2017 Automatic Sell 7,500 27.63
Jan 17, 2017 Automatic Sell 7,500 27.52
Dec 14, 2016 Automatic Sell 7,500 25.68
Dec 13, 2016 Automatic Sell 7,500 25.42
Nov 23, 2016 Automatic Sell 7,500 24.01
Nov 22, 2016 Automatic Sell 7,500 25.51
Mar 3, 2016 Disposition (Non Open Market) 9,146 15.48
Mar 3, 2016 Option Execute 28,021 n/a
Feb 12, 2016 Disposition (Non Open Market) 3,015 14.00
Feb 12, 2016 Option Execute 20,000 2.11
Dec 10, 2015 Automatic Sell 9,274 18.94
Dec 10, 2015 Option Execute 9,274 2.11
Nov 10, 2015 Automatic Sell 10,000 20.75
Nov 10, 2015 Option Execute 10,000 2.11
Nov 9, 2015 Automatic Sell 10,000 20.32
Nov 9, 2015 Option Execute 10,000 2.11
Oct 16, 2015 Automatic Sell 10,000 15.59
Oct 16, 2015 Option Execute 10,000 2.11
Oct 15, 2015 Automatic Sell 10,000 14.98
Oct 15, 2015 Option Execute 10,000 2.11
Sep 17, 2015 Automatic Sell 10,000 16.18
Sep 17, 2015 Option Execute 10,000 2.11
Sep 16, 2015 Automatic Sell 10,000 15.99
Sep 16, 2015 Option Execute 10,000 2.11
Aug 13, 2015 Automatic Sell 10,000 18.31
Aug 13, 2015 Option Execute 10,000 2.11
Aug 12, 2015 Automatic Sell 10,000 18.03
Aug 12, 2015 Option Execute 10,000 2.11
Jun 18, 2015 Automatic Sell 10,000 15.74
Jun 18, 2015 Option Execute 10,000 2.11
Jun 17, 2015 Automatic Sell 10,000 15.38
Jun 17, 2015 Option Execute 10,000 2.11
May 13, 2015 Automatic Sell 10,000 16.21
May 13, 2015 Option Execute 10,000 2.11
May 12, 2015 Automatic Sell 10,000 16.44
May 12, 2015 Option Execute 10,000 2.11
Apr 17, 2015 Automatic Sell 10,000 18.08
Apr 17, 2015 Option Execute 10,000 2.11
Apr 16, 2015 Automatic Sell 10,000 18.31
Apr 16, 2015 Option Execute 10,000 2.11

Heyward R. Donigan has served as a director of NxStage since July 2016. Ms. Donigan has served as President and Chief Executive Officer of Vitals, a leading consumer transparency company, since March 2015. From 2010 to 2014, Ms. Donigan served as President, Chief Executive Officer and a director of ValueOptions, Inc., a health improvement company specializing in mental and emotional wellbeing and recovery, which merged with Beacon Health Strategies during 2014. Previously, Ms. Donigan was Executive Vice President and Chief Marketing Officer of Premera Blue Cross, an insurer doing business in Washington, Alaska, and Oregon, from 2003 to 2010. With over 30 years of experience in all facets of the health plan business, including network management, contracting, sales and marketing, product development, and operations, Ms. Donigan brings strong experience within key areas to our Board. Return to Board of Directors.

Robert G. Funari, age 65, joined NxStage as a director in January, 2013.  Mr. Funari served as Chairman and Chief Executive Officer of Crescent Healthcare, a Walgreens Company providing integrated pharmacy and nursing solutions in alternate site settings from 2004 to 2012.  Prior to joining Crescent, Mr. Funari was Executive Vice President and Chief Operating Officer (1993-1996) at Syncor International Corporation, a publicly-traded radiopharmacy services company, where he also served as President and Chief Executive Officer (1996- 2003).  Mr. Funari was Executive Vice President and General Manager of the Drug Company for McKesson, Inc. and spent more than 18 years in a broad range of leadership positions at Baxter International.  

 Mr. Funari served as a director of Beckman Coulter, Inc., a diagnostics and life sciences company, where he was a member of the Compensation Committee from 2005 to 2011, as well as director of Pope and Talbot, Inc. where he was on the Governance and Compensation Committees from 2001 to 2008.  He also served as director of First Consulting Group from 2004 to 2008 and director of Bay Cities National Bank from 1994 to 2011 where he also served as chairman from 2007 to 2011.  He currently sits on the board of directors of a number of non-profit and private companies and is a member of the RAND Healthcare Board of Advisors.

 Mr. Funari holds a B.S. from Cornell University and a M.B.A. from Harvard Business School.  Mr. Funari received the Ernst & Young Entrepreneur Of The Year 2010 Award in the Turnaround category in Orange County/Desert cities.

 Mr. Funari’s executive leadership, particularly in the healthcare industry, and a proven track record of strategic planning and implementation, uniquely qualifies him to serve on our Board.

Daniel A. Giannini, age 61, has served as a director of NxStage since October 2005 and currently serves as chair of our Audit Committee and a member of our Nominating and Corporate Governance Committee. He also serves as a director on several private and non-profit company boards. Mr. Giannini retired in June 2005, after a more than 30-year career as a Certified Public Accountant with PricewaterhouseCoopers LLP. During his last five years at PricewaterhouseCoopers LLP, Mr. Giannini served as an audit partner and led the firm's Atlanta office's Technology, Information, Communications and Entertainment practice. Mr. Giannini received a B.S. degree in Business Administration from LaSalle University. Mr. Giannini brings corporate governance, internal control and financial reporting experience to the Board.

Recent Stock Transactions by Daniel A. Giannini C.P.A.
Date Type Shares Traded Price Range
Nov 21, 2016 Sell 6,449 25.96
Aug 4, 2016 Disposition (Non Open Market) 9,603 23.84
Aug 4, 2016 Option Execute 15,272 14.99
May 25, 2016 Disposition (Non Open Market) 13,807 18.81
May 25, 2016 Option Execute 14,000 18.55
Nov 9, 2015 Sell 6,593 20.30
Mar 13, 2015 Disposition (Non Open Market) 11,167 17.40
Mar 13, 2015 Option Execute 14,000 13.88
Jan 2, 2014 Option Execute 14,000 3.38
Mar 12, 2013 Disposition (Non Open Market) 6,720 11.23
Mar 12, 2013 Option Execute 14,000 5.39
Jun 29, 2012 Acquisition (Non Open Market) 809 n/a
Mar 30, 2012 Acquisition (Non Open Market) 713 n/a
Mar 14, 2012 Disposition (Non Open Market) 9,558 17.87
Mar 14, 2012 Option Execute 14,000 12.20
Dec 30, 2011 Acquisition (Non Open Market) 576 n/a
Sep 30, 2011 Acquisition (Non Open Market) 563 n/a
Jun 30, 2011 Acquisition (Non Open Market) 780 n/a
Mar 31, 2011 Acquisition (Non Open Market) 534 n/a
Mar 11, 2011 Disposition (Non Open Market) 7,407 20.47
Mar 11, 2011 Option Execute 14,000 10.83
Dec 31, 2010 Acquisition (Non Open Market) 130 n/a
Sep 30, 2010 Acquisition (Non Open Market) 772 n/a
Aug 13, 2010 Disposition (Non Open Market) 11,687 16.16
Aug 13, 2010 Option Execute 15,000 12.59
Jun 30, 2010 Acquisition (Non Open Market) 1,297 n/a
Mar 31, 2010 Acquisition (Non Open Market) 1,113 n/a
Dec 31, 2009 Acquisition (Non Open Market) 1,107 n/a
Earl R. Lewis, age 67, has served as a director of NxStage since October 2008 and currently serves as a member of our Compensation Committee. Since 2000, Mr. Lewis has been the Chairman, President and CEO of Flir Systems Inc., a manufacturer of thermal imaging and infrared camera systems. Prior to 2000, he served as CEO and President at Thermo Instrument Systems, Inc. He also served Thermo in various executive capacities, including President and Chief Operating Officer, CEO and President of Thermo Optek Corp., and President of Thermo Jarrell Ash Corp. In addition to serving on the board of Flir Systems, Inc., Mr. Lewis is a member of the Board of Directors of Harvard BioScience and American DG Energy, Inc. Mr. Lewis is a Trustee of Clarkson University and New Hampton School. Mr. Lewis holds a B.S. from Clarkson College of Technology and has attended post-graduate programs at the University of Buffalo, Northeastern University and Harvard University. Mr. Lewis has a professional Director Certification, earned through an extended series of director education programs sponsored by the Corporate Directors Group. Mr. Lewis brings leadership, general management, and large public company operational, financial and corporate experience to our Board.
Recent Stock Transactions by Earl R. Lewis
Date Type Shares Traded Price Range
Nov 2, 2016 Option Execute 33,468 13.60 - 14.99
May 25, 2016 Disposition (Non Open Market) 13,807 18.81
May 25, 2016 Option Execute 14,000 18.55
Feb 12, 2016 Buy 21,000 14.21 - 15.00
Nov 18, 2015 Sell 18,020 19.76
Feb 20, 2015 Option Execute 14,000 13.88
Jun 30, 2014 Acquisition (Non Open Market) 447 14.37
Mar 31, 2014 Acquisition (Non Open Market) 883 12.74
Dec 31, 2013 Acquisition (Non Open Market) 1,125 10.00
Sep 30, 2013 Acquisition (Non Open Market) 854 13.16
Jun 28, 2013 Acquisition (Non Open Market) 332 14.28
Jun 29, 2012 Acquisition (Non Open Market) 631 n/a
Mar 30, 2012 Acquisition (Non Open Market) 428 n/a
Dec 30, 2011 Acquisition (Non Open Market) 632 n/a
Sep 30, 2011 Acquisition (Non Open Market) 443 n/a
Jun 30, 2011 Acquisition (Non Open Market) 204 n/a
Mar 1, 2010 Option Execute 22,166 3.38 - 4.24

Jean K. Mixer, age 46, has served as a director of NxStage since November 2012. Since 2005, Ms. Mixer has been the Chief Executive Officer of mixerconsulting which helps organizations grow through strategic and governance work. Previously, from 1992-2004, she was at The Boston Consulting Group (BCG), a global strategy consulting firm, where she was a partner. She has worked across industries — biopharmaceuticals, medical device, retail pharmacy, PBMs, healthcare providers, insurance, and financing. Prior to BCG, Ms. Mixer was an officer at JP Morgan, New York.

Ms. Mixer is a Director on the Board of the Cambridge Trust Company and a member of the Executive Committee since 2006 and Chair of the Compensation Committee since 2010. She is also the Chair of the HR board committee for the Boys and Girls Clubs of Boston. Formerly, she served on the Business Round Table Committee on National Health Care Reform.

Ms. Mixer holds a Master's Degree in Management from the Kellogg School of Management and a BS with honors from Boston College.

Ms. Mixer brings 25 years of public company experience including strategy, mergers and acquisitions, finance, leadership, and governance to our board.

Craig W. Moore, age 66, has served as a director of NxStage since 2002 and currently serves as chair of our Compensation Committee and a member of our Audit Committee. Mr. Moore is also a member of Board of Directors of ThermoGenesis and serves on their Audit and Compensation Committees. Previously, Mr. Moore served on the board of Biologic System Corp. from 1992 to 2006. From 1986 to 2001, Mr. Moore was Chairman of the Board of Directors and Chief Executive Officer at Everest Healthcare Services Corporation, a provider of dialysis to patients with renal failure. Since 2001, Mr. Moore has acted as a consultant to various companies in the healthcare services industry. From 1986 through 2001, Mr. Moore was President of Continental Health Care, Ltd., an extracorporeal services and supply company, and from 1990 through 2004, he was President of New York Dialysis Management, a dialysis management business. Mr. Moore also serves as a director on several private company boards. Mr. Moore brings leadership, corporate and dialysis services industry experience to our Board.

Recent Stock Transactions by Craig W. Moore
Date Type Shares Traded Price Range
Mar 16, 2017 Sell 1,000 27.93
Feb 1, 2017 Disposition (Non Open Market) 8,568 26.72
Feb 1, 2017 Option Execute 15,272 14.99
Sep 14, 2016 Sell 1,500 23.60
Sep 12, 2016 Sell 1,500 23.02
May 25, 2016 Disposition (Non Open Market) 13,807 18.81
May 25, 2016 Option Execute 14,000 18.55
Nov 20, 2015 Automatic Sell 1,000 20.00
Nov 18, 2015 Automatic Sell 4,000 19.60
Sep 15, 2015 Sell 1,000 16.00
May 20, 2015 Disposition (Non Open Market) 11,478 16.93
May 20, 2015 Option Execute 14,000 13.88
Mar 5, 2014 Disposition (Non Open Market) 3,226 14.67
Mar 5, 2014 Option Execute 14,000 3.38
Mar 13, 2013 Disposition (Non Open Market) 6,637 11.37
Mar 13, 2013 Option Execute 14,000 5.39
May 24, 2012 Option Execute 14,000 12.20
Dec 15, 2011 Sell 10,000 17.25
Sep 14, 2011 Option Execute 18,791 3.76
Jun 30, 2011 Acquisition (Non Open Market) 488 n/a
May 25, 2011 Disposition (Non Open Market) 8,373 18.11
May 25, 2011 Option Execute 14,000 10.83
Mar 31, 2011 Acquisition (Non Open Market) 489 n/a
Dec 31, 2010 Acquisition (Non Open Market) 472 n/a
Sep 30, 2010 Acquisition (Non Open Market) 615 n/a
Jul 27, 2010 Sell 8,945 16.89
Jul 27, 2010 Option Execute 12,000 12.59
Jun 30, 2010 Acquisition (Non Open Market) 825 n/a
Mar 31, 2010 Acquisition (Non Open Market) 1,026 n/a
Dec 31, 2009 Acquisition (Non Open Market) 808 n/a

Reid S. Perper, age 51, has served as a director of NxStage since September 2005 and currently serves as a member of our Audit Committee. Since September 2008, Mr. Perper has been a founder and partner of MCT Advisors LLP, a London based financial advisory firm. From January 2004 to March 2009, Mr. Perper was Managing Director of Healthcare Investment Partners LLC. From November 2000 through June 2003, Mr. Perper was a Managing Director and Co-Head of Europe for CSFB Private Equity. Prior to joining CSFB, Mr. Perper was a Managing Director of DLJ Merchant Banking Partners. Mr. Perper joined Donaldson, Lufkin & Jenrette in 1988. Mr. Perper also served as an investment professional for Caxton Europe Asset Management Ltd. from May 2004 through July 2005. Mr. Perper brings over 20 years of experience in private equity, as well as strategic and capital market experience, particularly within medical devices, healthcare services, pharmaceuticals and biotechnology, to our Board.

Recent Stock Transactions by Reid S. Perper
Date Type Shares Traded Price Range
Mar 10, 2017 Disposition (Non Open Market) 8,221 27.85
Mar 10, 2017 Option Execute 15,272 14.99
May 25, 2016 Disposition (Non Open Market) 6,904 18.81
May 25, 2016 Option Execute 7,000 18.55
Nov 10, 2015 Disposition (Non Open Market) 6,280 20.68
Nov 10, 2015 Option Execute 7,000 18.55
Mar 17, 2015 Disposition (Non Open Market) 11,148 17.43
Mar 17, 2015 Option Execute 14,000 13.88
Dec 11, 2013 Option Execute 14,000 3.38
Mar 5, 2013 Disposition (Non Open Market) 6,867 10.99
Mar 5, 2013 Option Execute 14,000 5.39
May 24, 2012 Disposition (Non Open Market) 11,395 14.99
May 24, 2012 Option Execute 14,000 12.20
Sep 14, 2011 Sell 30,000 18.84 - 19.55
Aug 31, 2011 Sell 28,540 18.71
Aug 30, 2011 Sell 30,000 18.44
Aug 29, 2011 Sell 20,000 18.42
Jun 30, 2011 Acquisition (Non Open Market) 392 n/a
May 25, 2011 Disposition (Non Open Market) 4,187 18.11
May 25, 2011 Option Execute 7,000 10.83
May 6, 2011 Disposition (Non Open Market) 3,774 20.09
May 6, 2011 Option Execute 7,000 10.83
Mar 31, 2011 Acquisition (Non Open Market) 398 n/a
Dec 31, 2010 Acquisition (Non Open Market) 351 n/a
Sep 30, 2010 Acquisition (Non Open Market) 510 n/a
Jul 27, 2010 Sell 8,945 16.89
Jul 27, 2010 Option Execute 12,000 12.59
Jun 30, 2010 Acquisition (Non Open Market) 724 n/a
Mar 31, 2010 Acquisition (Non Open Market) 851 n/a
Dec 31, 2009 Acquisition (Non Open Market) 1,167 n/a

James J. Peters has served as a director of NxStage since 2016. Mr. Peters joined Geisinger Health System in 2004, and has been a key part of the leadership team that established Geisinger’s national reputation for healthcare innovation. As Senior Vice President and Chief Strategic Partnerships Officer, Mr. Peters has led Geisinger’s corporate development transactions with industry and served as joint governance committee Chair for numerous product co-development partnerships with Fortune 100 companies. As Chief Executive Officer of Geisinger Medical Management Corporation, Geisinger’s for-profit enterprise, Mr. Peters has had overall P&L responsibility for its portfolio of entrepreneurial businesses spanning health information services, home-based patient monitoring, clinical engineering, retail care clinics, specialty pharmacy, and personalized diagnostics. From 2002 to 2004, Mr. Peters served as Principal at Updata Venture Partners, a $450M venture capital firm with a focus on growth stage software and health IT companies. From 1998-2002, Mr. Peters founded and grew a successful New York City-based software services firm that serviced and sold into the medical technology sector. From 1994 to 1998, Mr. Peters was a senior consultant in the enterprise software practice at Andersen Consulting in New York. In addition to over 20+ years of executive leadership, venture investment, business building, health IT, and provider-payer-manufacturer partnership experience, Mr. Peters brings a strong track record of developing and scaling a culture of innovation within a complex healthcare enterprise to our Board.

Stock transaction information provided by EDGAR Online. NxStage Medical, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.

  Audit Nominating and Governance Compensation
Heyward R. Donigan
Heyward R. Donigan

Heyward R. Donigan has served as a director of NxStage since July 2016. Ms. Donigan has served as President and Chief Executive Officer of Vitals, a leading consumer transparency company, since March 2015. From 2010 to 2014, Ms. Donigan served as President, Chief Executive Officer and a director of ValueOptions, Inc., a health improvement company specializing in mental and emotional wellbeing and recovery, which merged with Beacon Health Strategies during 2014. Previously, Ms. Donigan was Executive Vice President and Chief Marketing Officer of Premera Blue Cross, an insurer doing business in Washington, Alaska, and Oregon, from 2003 to 2010. With over 30 years of experience in all facets of the health plan business, including network management, contracting, sales and marketing, product development, and operations, Ms. Donigan brings strong experience within key areas to our Board. Return to Board of Directors.

   
Robert G. Funari
Robert G. Funari

Robert G. Funari, age 65, joined NxStage as a director in January, 2013.  Mr. Funari served as Chairman and Chief Executive Officer of Crescent Healthcare, a Walgreens Company providing integrated pharmacy and nursing solutions in alternate site settings from 2004 to 2012.  Prior to joining Crescent, Mr. Funari was Executive Vice President and Chief Operating Officer (1993-1996) at Syncor International Corporation, a publicly-traded radiopharmacy services company, where he also served as President and Chief Executive Officer (1996- 2003).  Mr. Funari was Executive Vice President and General Manager of the Drug Company for McKesson, Inc. and spent more than 18 years in a broad range of leadership positions at Baxter International.  

 Mr. Funari served as a director of Beckman Coulter, Inc., a diagnostics and life sciences company, where he was a member of the Compensation Committee from 2005 to 2011, as well as director of Pope and Talbot, Inc. where he was on the Governance and Compensation Committees from 2001 to 2008.  He also served as director of First Consulting Group from 2004 to 2008 and director of Bay Cities National Bank from 1994 to 2011 where he also served as chairman from 2007 to 2011.  He currently sits on the board of directors of a number of non-profit and private companies and is a member of the RAND Healthcare Board of Advisors.

 Mr. Funari holds a B.S. from Cornell University and a M.B.A. from Harvard Business School.  Mr. Funari received the Ernst & Young Entrepreneur Of The Year 2010 Award in the Turnaround category in Orange County/Desert cities.

 Mr. Funari’s executive leadership, particularly in the healthcare industry, and a proven track record of strategic planning and implementation, uniquely qualifies him to serve on our Board.

 
Daniel A. Giannini C.P.A.
Daniel A. Giannini C.P.A.

Daniel A. Giannini, age 61, has served as a director of NxStage since October 2005 and currently serves as chair of our Audit Committee and a member of our Nominating and Corporate Governance Committee. He also serves as a director on several private and non-profit company boards. Mr. Giannini retired in June 2005, after a more than 30-year career as a Certified Public Accountant with PricewaterhouseCoopers LLP. During his last five years at PricewaterhouseCoopers LLP, Mr. Giannini served as an audit partner and led the firm's Atlanta office's Technology, Information, Communications and Entertainment practice. Mr. Giannini received a B.S. degree in Business Administration from LaSalle University. Mr. Giannini brings corporate governance, internal control and financial reporting experience to the Board.

   
Earl R. Lewis
Earl R. Lewis
Earl R. Lewis, age 67, has served as a director of NxStage since October 2008 and currently serves as a member of our Compensation Committee. Since 2000, Mr. Lewis has been the Chairman, President and CEO of Flir Systems Inc., a manufacturer of thermal imaging and infrared camera systems. Prior to 2000, he served as CEO and President at Thermo Instrument Systems, Inc. He also served Thermo in various executive capacities, including President and Chief Operating Officer, CEO and President of Thermo Optek Corp., and President of Thermo Jarrell Ash Corp. In addition to serving on the board of Flir Systems, Inc., Mr. Lewis is a member of the Board of Directors of Harvard BioScience and American DG Energy, Inc. Mr. Lewis is a Trustee of Clarkson University and New Hampton School. Mr. Lewis holds a B.S. from Clarkson College of Technology and has attended post-graduate programs at the University of Buffalo, Northeastern University and Harvard University. Mr. Lewis has a professional Director Certification, earned through an extended series of director education programs sponsored by the Corporate Directors Group. Mr. Lewis brings leadership, general management, and large public company operational, financial and corporate experience to our Board.
   
Jean K. Mixer
Jean K. Mixer

Jean K. Mixer, age 46, has served as a director of NxStage since November 2012. Since 2005, Ms. Mixer has been the Chief Executive Officer of mixerconsulting which helps organizations grow through strategic and governance work. Previously, from 1992-2004, she was at The Boston Consulting Group (BCG), a global strategy consulting firm, where she was a partner. She has worked across industries — biopharmaceuticals, medical device, retail pharmacy, PBMs, healthcare providers, insurance, and financing. Prior to BCG, Ms. Mixer was an officer at JP Morgan, New York.

Ms. Mixer is a Director on the Board of the Cambridge Trust Company and a member of the Executive Committee since 2006 and Chair of the Compensation Committee since 2010. She is also the Chair of the HR board committee for the Boys and Girls Clubs of Boston. Formerly, she served on the Business Round Table Committee on National Health Care Reform.

Ms. Mixer holds a Master's Degree in Management from the Kellogg School of Management and a BS with honors from Boston College.

Ms. Mixer brings 25 years of public company experience including strategy, mergers and acquisitions, finance, leadership, and governance to our board.

 
Craig W. Moore
Craig W. Moore

Craig W. Moore, age 66, has served as a director of NxStage since 2002 and currently serves as chair of our Compensation Committee and a member of our Audit Committee. Mr. Moore is also a member of Board of Directors of ThermoGenesis and serves on their Audit and Compensation Committees. Previously, Mr. Moore served on the board of Biologic System Corp. from 1992 to 2006. From 1986 to 2001, Mr. Moore was Chairman of the Board of Directors and Chief Executive Officer at Everest Healthcare Services Corporation, a provider of dialysis to patients with renal failure. Since 2001, Mr. Moore has acted as a consultant to various companies in the healthcare services industry. From 1986 through 2001, Mr. Moore was President of Continental Health Care, Ltd., an extracorporeal services and supply company, and from 1990 through 2004, he was President of New York Dialysis Management, a dialysis management business. Mr. Moore also serves as a director on several private company boards. Mr. Moore brings leadership, corporate and dialysis services industry experience to our Board.

   
Reid S. Perper
Reid S. Perper

Reid S. Perper, age 51, has served as a director of NxStage since September 2005 and currently serves as a member of our Audit Committee. Since September 2008, Mr. Perper has been a founder and partner of MCT Advisors LLP, a London based financial advisory firm. From January 2004 to March 2009, Mr. Perper was Managing Director of Healthcare Investment Partners LLC. From November 2000 through June 2003, Mr. Perper was a Managing Director and Co-Head of Europe for CSFB Private Equity. Prior to joining CSFB, Mr. Perper was a Managing Director of DLJ Merchant Banking Partners. Mr. Perper joined Donaldson, Lufkin & Jenrette in 1988. Mr. Perper also served as an investment professional for Caxton Europe Asset Management Ltd. from May 2004 through July 2005. Mr. Perper brings over 20 years of experience in private equity, as well as strategic and capital market experience, particularly within medical devices, healthcare services, pharmaceuticals and biotechnology, to our Board.

 
James J. Peters
James J. Peters

James J. Peters has served as a director of NxStage since 2016. Mr. Peters joined Geisinger Health System in 2004, and has been a key part of the leadership team that established Geisinger’s national reputation for healthcare innovation. As Senior Vice President and Chief Strategic Partnerships Officer, Mr. Peters has led Geisinger’s corporate development transactions with industry and served as joint governance committee Chair for numerous product co-development partnerships with Fortune 100 companies. As Chief Executive Officer of Geisinger Medical Management Corporation, Geisinger’s for-profit enterprise, Mr. Peters has had overall P&L responsibility for its portfolio of entrepreneurial businesses spanning health information services, home-based patient monitoring, clinical engineering, retail care clinics, specialty pharmacy, and personalized diagnostics. From 2002 to 2004, Mr. Peters served as Principal at Updata Venture Partners, a $450M venture capital firm with a focus on growth stage software and health IT companies. From 1998-2002, Mr. Peters founded and grew a successful New York City-based software services firm that serviced and sold into the medical technology sector. From 1994 to 1998, Mr. Peters was a senior consultant in the enterprise software practice at Andersen Consulting in New York. In addition to over 20+ years of executive leadership, venture investment, business building, health IT, and provider-payer-manufacturer partnership experience, Mr. Peters brings a strong track record of developing and scaling a culture of innovation within a complex healthcare enterprise to our Board.

   
= Chair of the Board = Chair = Member = Independent Director

Stock transaction information provided by EDGAR Online. NxStage Medical, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.